

31 August 2015

Suite 1, 1233 High Street
Armadale VIC 3142

Imugene Announces Annual Results For The Year Ended 30 June 2015

- Cash and cash equivalents at 30 June 2015 of \$2.0m: up 60% on previous year;
- Phase 1b/2 trial in advanced planning, with recruitment planned for last quarter of 2015;
- R&D tax credit of \$0.55m expected in FY 2016; and
- New study planned to support orphan drug application with FDA and to steer development of additional clinical candidates using HER-Vaxx.

Imugene Limited (ASX: IMU) announced a total loss of \$2.4m on its operations for the year ended 30 June 2015. This included an impairment expense on \$0.3m on the discontinued Linguet asset. During the year, the Company incurred expenditure of \$3.1m, which was partly offset by an expected rebate of \$0.5m under the Australian Government's R&D tax incentive scheme. The majority of expenses, being \$1.7m, were incurred on research & development, with the balance being business development, finance and administration costs.

Operational highlights during the period included the appointment of Simbec-Orion, a specialised CRO, to conduct the Phase 1b/2 clinical trial. Patient recruitment in Australia and Europe will commence in the last quarter of 2015.

During the year Imugene improved upon the already strong formulation with the new use of CRM197 as a vaccine conjugate in place of the more complicated and costly virosomes, but have finalised the peptide element to be highly immunogenic, and the resulting HER-Vaxx is cheaper, easier to make and above all the most potent combination Imugene has ever had.

Imugene is also in the later stages of planning to conduct a new preclinical study of HER-Vaxx in an additional disease model of gastric cancer. This work has the benefit of improving Imugene's case to achieve orphan drug designation from the United States FDA, but could also steer the development of follow up clinical candidates using the HER-Vaxx technology.

Chief Scientific Officer (CSO), Prof. Dr. Ursula Wiedermann, is conducting additional work at the Medical University of Vienna on the final chosen formulation of HER-Vaxx. This work is looking to further establish additional evidence of the enhanced efficacy from the new (CRM197) formulation of HER-Vaxx. Imugene filed for an additional patent, which if granted will refresh the patent life to 2036, which is significantly greater than average and would directly extend the period of time which HER-Vaxx can enjoy a monopoly position in the market.

Imugene announced the appointment of Ms Leslie Chong to the position of Chief Operating Officer. Leslie has extensive involvement in planning and implementing optimal clinical trial strategies for immuno-oncology drugs and she is in familiar territory with HER-Vaxx.

For personal use only

Paul Hopper, Executive Chairman said "The Company thanks shareholders for their continued support and looks forward to further progressing the development of its HER-Vaxx technology and beginning its next clinical trial within months. We look forward to keeping shareholders updated with a number of interesting developments in the coming months."

For more information, please contact:

Imugene:

Paul Hopper

Executive Chairman

61 (0) 406 671 515

receptogen[at]earthlink.net

About Imugene:

Imugene (ASX; IMU) is a clinical stage immuno-oncology company developing HER-2+ gastric and breast cancer immunotherapies. The Company's lead product is HER-Vaxx, a proprietary HER-2 positive cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu. HER-2/neu is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has successfully completed a Phase 1 study in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer.